Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Siyang Leng
- Target Recruit Count
- 20
- Registration Number
- NCT02002598
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 311
- Registration Number
- NCT01980888
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇨🇦Cancercare Manitoba - Maccharles Unit, Winnipeg, Manitoba, Canada
🇺🇸Franciscan Physician Network Oncology & Hematology, Indianapolis, Indiana, United States
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 403
- Registration Number
- NCT01974440
A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 73
- Registration Number
- NCT01929265
- Locations
- 🇮🇹
SC Ematologia - AO SS. Antonio e Biagio e C. Arrigo, Alessandria, AL, Italy
🇮🇹Divisione di Ematologia Ospedale Niguarda, Milano, MI, Italy
🇮🇹Centro Oncologico Modenese, Modena, MO, Italy
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 979
- Registration Number
- NCT01905943
- Locations
- 🇧🇷
Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil
🇧🇷Hospital de Cancer de Barretos, Barretos, SP, Brazil
🇧🇷Hospital Amaral Carvalho, Jau, SP, Brazil
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT01900509
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 40
- Registration Number
- NCT01891227
- Locations
- 🇦🇹
KH Barmh. Schwestern Linz, Innere Medizin I Hämatologie/Onkologie, Linz, Austria
🇦🇹Universitätsklinik f. Frauenheilkunde und Geburtshilfe, Klin. Abt. f. Gynäkologie, Graz, Austria
🇦🇹Hämatologie und Onkologie/Interne E, LKH Feldkirch, Feldkirch, Austria
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
- Conditions
- Interventions
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 159
- Registration Number
- NCT01889069
- Locations
- 🇮🇹
Az. Osp. Carlo Poma; Divisione Di Oncologia Medica, Mantova, Lombardia, Italy
🇮🇹Seconda università degli studi di napoli; Medicina clinica e sperimentale magrassi - lanzara, Napoli, Campania, Italy
🇮🇹ASST DI CREMA; U O Oncologia Medica, Crema, Lombardia, Italy
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 547
- Registration Number
- NCT01886872
- Locations
- 🇺🇸
Wayne Hospital, Greenville, Ohio, United States
🇺🇸Cleveland Clinic Cancer Center Independence, Independence, Ohio, United States
🇺🇸Diagnostic and Treatment Center, Weston, Wisconsin, United States
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Armando Santoro, MD
- Target Recruit Count
- 59
- Registration Number
- NCT01884441
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, MI, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.